相关实验视频
Updated: Jul 9, 2025

09:15
In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
614
根据FDA不良事件报告系统数据,对药物诱导的血小板缺血进行了更新的综合药监研究
Li Kunyu1,2, Shi Shuping2, Su Chang3
1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Journal of clinical pharmacology
|December 2, 2023
概括
这项研究分析了FDA的数据,以识别导致血小板缺血的药物. 它发现包括lenalidomide和niraparib在内的几种药物经常与这种严重疾病有关.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 血液学 血液学 血液学
背景情况:
- 药物诱导的血小板缺血 (DIT) 是一个重要的临床问题,因为它的流行率和严重的后果.
- 了解与DIT相关的药物关联对于患者安全和临床管理至关重要.
研究的目的:
- 使用FDA不良事件报告系统 (FAERS) 数据库对DIT进行全面的药监测分析.
- 为了确定与血小板缺血事件相关的特定药物和药物类别.
主要方法:
- 2004年1月至2022年12月向FAERS报告的DIT事件的不成比例分析.
- 应用信息组件 (IC) 和报告几率比率 (ROR) 算法来检测药物-DIT关联.
- 分析了超过1590万个案例,包括168657个与DIT相关的事件.
主要成果:
- 莱纳利多米德,尼拉巴里布和肝素是DIT病例数量最高的药物之一.
- 达纳帕洛伊德 (Danaparoid),埃普蒂菲巴提德 (eptifibatide) 和伊诺特森 (inotersen) 显示出与DIT相关的信号强度最高.
- 蛋白激酶抑制剂,抗代谢物和抗体-药物合物是最常被涉及的药物组.
结论:
- 这项药监测研究发现了许多与血小板缺血相关的药物.
- 需要进一步的研究来阐明许多涉及的药物的DIT机制.
相关概念视频
Pharmacovigilance
850
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
850
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
532
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
532
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Therapeutic Index
4.3K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.3K

